Corisin, a 19 amino acid proapoptotic peptide derived from the lung microbiota (i.e., by Staphylococci), is implicated in the pathogenesis of acute lung injury and exacerbation of pulmonary fibrosis. Recent evidence also suggests that this molecule may have a role in lung thrombosis, as its concentration correlates with a prothrombotic state. It has also been demonstrated that corisin inhibition by using monoclonal antibodies is effective inhibiting pulmonary fibrosis and venous thrombosis in patients with coronavirus disease 2019 (COVID-19). Further studies should hence be planned to verify whether anti-corisin immunotherapy could become a reliable therapeutic perspective against the risk of developing COVID-19 coagulopathy.
Anti-corisin immunotherapy: therapeutic perspective for reducing the risk of developing COVID-19 coagulopathy?
Giuseppe, Lippi
2024-01-01
Abstract
Corisin, a 19 amino acid proapoptotic peptide derived from the lung microbiota (i.e., by Staphylococci), is implicated in the pathogenesis of acute lung injury and exacerbation of pulmonary fibrosis. Recent evidence also suggests that this molecule may have a role in lung thrombosis, as its concentration correlates with a prothrombotic state. It has also been demonstrated that corisin inhibition by using monoclonal antibodies is effective inhibiting pulmonary fibrosis and venous thrombosis in patients with coronavirus disease 2019 (COVID-19). Further studies should hence be planned to verify whether anti-corisin immunotherapy could become a reliable therapeutic perspective against the risk of developing COVID-19 coagulopathy.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
